000 02844nam a22004455i 4500
001 60598
005 20200226102408.0
007 cr nn 008mamaa
008 161101s2017 si | s |||| 0|eng d
020 _a9789811024160
_9978-981-10-2416-0
024 7 _a10.1007/978-981-10-2416-0
_2doi
035 _a(DE-He213)978-981-10-2416-0
050 4 _aRC841-858.P35
072 7 _aMJJ
_2bicssc
072 7 _aMED031000
_2bisacsh
082 0 4 _a616.36
_223
245 1 0 _aHepatitis C Virus Treatment
_h[electronic resource] :
_bHighly Effective Therapy with Direct Acting Antivirals and Associated Viral Resistance /
_cedited by Kazuaki Chayama.
264 1 _aSingapore :
_bSpringer Singapore :
_bImprint: Springer,
_c2017.
300 _aVII, 75 p. 23 illus., 14 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
520 _aThis book introduces readers to Direct Acting Antiviral (DAAs) agents, newly developed drugs to treat chronic hepatitis C virus infection, which have an excellent anti-viral effect on virus replication. These drugs have been developed to enhance the effect of interferon and ribavirin, as the resistant strains against each drug have been described both in vitro and in vivo and the existences of naturally occurring variants have been reported. However, since the combination of different classes of DAAs is sufficient to completely eradicate the virus without the need for interferon or ribavirin, the current treatment regimen does not include interferon. Ribavirin is used in combination with sofosbuvir, a potent polymerase inhibitor, to enhance its antiviral effects. Hepatitis C Virus Treatment offers readers a comprehensive guide to hepatitis C; describing the resistance profiles against these drugs and shedding light on the difficulties involved in DAA therapy and the direction of future treatments, it will equip doctors to understand the essentials of treating the disease. It also describes in detail new and innovative DAA treatments, the effects of the agents, and the characteristics of resistance, providing cutting-edge information not only for hepatologists, but also for researchers, clinical residents, and medical students.
650 0 _aMedicine.
650 0 _aDrug resistance.
650 0 _aVirology.
650 0 _aHepatology.
650 1 4 _aMedicine & Public Health.
650 2 4 _aHepatology.
650 2 4 _aVirology.
650 2 4 _aDrug resistance.
700 1 _aChayama, Kazuaki.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9789811024153
856 4 0 _uhttp://dx.doi.org/10.1007/978-981-10-2416-0
912 _aZDB-2-SME
999 _c3357
_d3357